Literature DB >> 1877715

Infection of Aedes albopictus and Aedes aegypti mosquitoes with dengue parent and progeny candidate vaccine viruses: a possible marker of human attenuation.

R J Schoepp1, B J Beaty, K H Eckels.   

Abstract

Dengue (DEN-1) and DEN-4 parent (P) and progeny candidate vaccine (CV) viruses were compared in their abilities to infect and to replicate in Aedes aegypti and Aedes albopictus mosquitoes. The DEN CV clones were temperature sensitive (ts) and had small plaque morphology. The DEN-1 and DEN-4 CV viruses differed in their ability to infect, to replicate in, and to be transmitted by mosquitoes. The DEN-1 CV virus was not attenuated for the vector mosquitoes; oral infection rates with the CV virus were as high as or higher than the P virus, and the CV virus replicated efficiently in mosquitoes after oral infection. The DEN-4 CV virus was attenuated; it was less efficient than its P virus in infection and replication in mosquitoes. Thus, the ts phenotype and small plaque morphology are not reliable biological markers for prediction of vector attenuation. Similar results were reported by others for attenuation in man and monkeys. These studies with DEN-1 and DEN-4 viruses, and previously reported studies with DEN-2 virus and with DEN-3 virus suggest that vector and vertebrate host attenuation are genetically linked. Thus, vector attenuation may be a biological marker for human attenuation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1877715     DOI: 10.4269/ajtmh.1991.45.202

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  6 in total

1.  Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.

Authors:  Claire Y-H Huang; Siritorn Butrapet; Kiyotaka R Tsuchiya; Natth Bhamarapravati; Duane J Gubler; Richard M Kinney
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.

Authors:  S Butrapet; C Y Huang; D J Pierro; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.

Authors:  C Y Huang; S Butrapet; D J Pierro; G J Chang; A R Hunt; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 4.  Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission.

Authors:  Louis Lambrechts; Thomas W Scott; Duane J Gubler
Journal:  PLoS Negl Trop Dis       Date:  2010-05-25

5.  Testing of novel dengue virus 2 vaccines in African green monkeys: safety, immunogenicity, and efficacy.

Authors:  Katherine M Smith; Kavita Nanda; Carla J Spears; Amanda Piper; Mariana Ribeiro; Michelle Quiles; Caitlin M Briggs; Gwynneth S Thomas; Malcolm E Thomas; Dennis T Brown; Raquel Hernandez; Victoria McCarl
Journal:  Am J Trop Med Hyg       Date:  2012-08-13       Impact factor: 2.345

6.  Dengue virus type 2: replication and tropisms in orally infected Aedes aegypti mosquitoes.

Authors:  Ma Isabel Salazar; Jason H Richardson; Irma Sánchez-Vargas; Ken E Olson; Barry J Beaty
Journal:  BMC Microbiol       Date:  2007-01-30       Impact factor: 3.605

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.